{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T06:56:21Z","timestamp":1697612181445},"reference-count":142,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"vor","delay-in-days":61,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Clin Exp Hematol"],"published-print":{"date-parts":[[2002,9]]},"abstract":"<jats:p>There has been no improvement in the treatment of multiple myeloma (MM) during the last decades and two meta\u2010analyses of randomized trials recorded no significant survival benefit for combination chemotherapy compared to the classic melphalan\u2010prednisone combination. However the past 15 years has seen several innovative strategies which have dramatically modified the management of MM. In younger patients, high\u2010dose therapy with autologous stem cell transplantation is considered to be superior to conventional chemotherapy and is used as part of front\u2010line therapy. A number of issues have been addressed in recent trials in order to improve the results of autologous transplantation (source of stem cells, conditioning regimen, impact of double transplants, maintenance therapy). Bisphosphonates reduce the incidence of skeletal\u2010related events and improve the quality of life. Recombinant erythropoietin reduces red blood cell transfusion need and improves the quality of life. Thalidomide has been introduced more recently. Phase II studies with thalidomide alone or combined with dexamethasone have shown impressive response rates and this drug is currently being evaluated as part of front\u2010line therapy. Finally, analysis of prognostic factors such as <jats:italic>\u03b2<\/jats:italic>2 microglobulin and cytogenetics define subgroups of patients with a completely different outcome and help the process of selecting therapeutics strategies.<\/jats:p>","DOI":"10.1046\/j.1468-0734.2002.00077.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T19:09:12Z","timestamp":1047496152000},"page":"253-275","source":"Crossref","is-referenced-by-count":9,"title":["M<scp>ANAGEMENT<\/scp><scp> OF<\/scp> M<scp>ULTIPLE<\/scp> M<scp>YELOMA<\/scp>"],"prefix":"10.1111","volume":"6","author":[{"given":"Jean\u2010Luc","family":"Harousseau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,11]]},"reference":[{"key":"e_1_2_12_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.50.1.7"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01133202"},{"key":"e_1_2_12_4_2","first-page":"1862","volume-title":"Principles and Practices of Oncology","author":"Salmon SE","year":"1989"},{"key":"e_1_2_12_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706053362307"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402173300709"},{"key":"e_1_2_12_7_2","first-page":"61","article-title":"The role of autologous hematopoietic stem cell transplantation in multiple myeloma.","volume":"34","author":"Harousseau JL","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_12_8_2","doi-asserted-by":"crossref","unstructured":"Guidelines on the diagnosisandmanagement of multiple myeloma.Br J Haematol 115:522\u2013544.2001.","DOI":"10.1046\/j.1365-2141.2001.03206.x"},{"key":"e_1_2_12_9_2","first-page":"300","article-title":"Staging and kinetics of multiple myeloma.","volume":"13","author":"Durie BGM.","year":"1986","journal-title":"Semin Oncol"},{"key":"e_1_2_12_10_2","first-page":"24","article-title":"Advances in the diagnosis and management of myeloma.","volume":"29","author":"Greipp P.","year":"1992","journal-title":"Semin Hematol"},{"key":"e_1_2_12_11_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/JCO.1993.11.7.1311","article-title":"Magnetic resonance imaging in the staging of solitary plasmacytoma of bone.","volume":"11","author":"Moulopoulos LA","year":"1993","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb00148.x"},{"key":"e_1_2_12_13_2","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long\u2010term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicenter randomized study.","volume":"82","author":"Riccardi A","year":"2000","journal-title":"Br J Cancer"},{"key":"e_1_2_12_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1122939.x"},{"key":"e_1_2_12_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01244.x"},{"key":"e_1_2_12_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.328"},{"key":"e_1_2_12_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5750.640"},{"key":"e_1_2_12_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.8.453"},{"key":"e_1_2_12_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90004-M"},{"key":"e_1_2_12_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.334"},{"key":"e_1_2_12_21_2","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy vs. melphalan plus prednisone as treatment for multiple myeloma: an overview of 6.633 patients from 27 randomized trials.","volume":"16","author":"Myeloma Trialists\u2019 Collaborative Group.","year":"1998","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_22_2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/blood.V85.2.588.588","article-title":"Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.","volume":"85","author":"Tricot G","year":"1995","journal-title":"Blood"},{"key":"e_1_2_12_23_2","first-page":"937","article-title":"Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.","volume":"17","author":"Demirer T","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_12_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102104"},{"key":"e_1_2_12_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91549-3"},{"key":"e_1_2_12_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91548-1"},{"key":"e_1_2_12_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2122.x"},{"key":"e_1_2_12_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-1-8"},{"key":"e_1_2_12_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"e_1_2_12_30_2","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064.409k07_3064_3073","article-title":"Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase\u20102 secretion parallel progression of human multiple myeloma.","volume":"93","author":"Vacca A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_12_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_12_32_2","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.","volume":"96","author":"Hideshima T","year":"2000","journal-title":"Blood"},{"key":"e_1_2_12_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"e_1_2_12_34_2","unstructured":"Grosbois B Bellissant E Moreau P et al.Thalidomide in the treatment of advanced multiple myeloma. A prospective study of 120 patients. Abstract 689. American Society of Haematology Orlando 2001."},{"key":"e_1_2_12_35_2","first-page":"408","article-title":"Salvage therapy with Thalidomide for patients with relapsed\/refractory multiple myeloma.","volume":"87","author":"Tosi P","year":"2002","journal-title":"Hematologica"},{"key":"e_1_2_12_36_2","first-page":"404","article-title":"Thalidomide treatment of resistant or relapsed multiple myeloma patients.","volume":"86","author":"Hus M","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_12_37_2","first-page":"1","article-title":"Efficacies of low dose Thalidomide in multiple myeloma.","volume":"1","author":"Durie BGM","year":"2000","journal-title":"Electronic J Oncol"},{"key":"e_1_2_12_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200031"},{"key":"e_1_2_12_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01983.x"},{"key":"e_1_2_12_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01835.x"},{"key":"e_1_2_12_41_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011132808904"},{"key":"e_1_2_12_42_2","first-page":"399","article-title":"Low\u2010dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma patients.","volume":"86","author":"Palumbo A","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_12_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402183"},{"key":"e_1_2_12_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3846"},{"key":"e_1_2_12_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1614"},{"key":"e_1_2_12_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"e_1_2_12_47_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026548226770"},{"key":"e_1_2_12_48_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-2-199601150-00004"},{"key":"e_1_2_12_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1802.x"},{"key":"e_1_2_12_50_2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.","volume":"89","author":"Barlogie B","year":"1997","journal-title":"Blood"},{"key":"e_1_2_12_51_2","first-page":"7","article-title":"Impact of survival of high\u2010dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma.","volume":"95","author":"Lenhoff S","year":"2000","journal-title":"Blood"},{"key":"e_1_2_12_52_2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.V94.4.1248","article-title":"Dose intensive melphalan with stem\u2010cell support is superior to standard treatment in elderly myeloma patients.","volume":"94","author":"Palumbo A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_12_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2167"},{"key":"e_1_2_12_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_12_55_2","unstructured":"Fermand JP Ravaud P Katsahian S et al.High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55\u201365 years of age.Blood94(Suppl. 1): 396a (Abstract) 1999."},{"key":"e_1_2_12_56_2","unstructured":"Blade J Sureda A Ribera JM et al.High\u2010dose therapy autotransplantation\/intensification vs. continued conventional chemotherapy in multiple myeloma in patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative Group PETHEMA.Blood98815a (Abstract) 2001."},{"key":"e_1_2_12_57_2","unstructured":"Palumbo A Bringhen S Rus C et al.A prospective randomized trial of intermediate dose melphalan (100\u2003mg\/m2) vs. oral melphalan\/prednisone: an interim analysis.Blood849a (Abstract) 2001."},{"key":"e_1_2_12_58_2","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High\u2010dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up\u2010front or resume treatment? Results of a multicenter sequential randomized clinical trial.","volume":"92","author":"Fermand JP","year":"1998","journal-title":"Blood"},{"key":"e_1_2_12_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.759"},{"key":"e_1_2_12_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.731"},{"key":"e_1_2_12_61_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood.V86.1.390.bloodjournal861390","article-title":"Transplantation of CD 34+ peripheral blood progenitor cell after high\u2010dose chemotherapy for patients with advanced multiple myeloma.","volume":"86","author":"Schiller G","year":"1995","journal-title":"Blood"},{"key":"e_1_2_12_62_2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1182\/blood.V87.4.1625.bloodjournal8741625","article-title":"Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD 34+ cells to remove circulating tumor cells.","volume":"87","author":"Lemoli RM","year":"1996","journal-title":"Blood"},{"key":"e_1_2_12_63_2","first-page":"1858","article-title":"Multicenter Phase III trial to evaluate CD 34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.","volume":"93","author":"Vescio RA","year":"1999","journal-title":"Blood"},{"key":"e_1_2_12_64_2","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1200\/JCO.2001.19.17.3771","article-title":"Purging of autologous peripheral blood stem cells using CD34 selection does not improve overall or progression free survival after high\u2010dose therapy for multiple myeloma: results of a multicenter randomized controlled trial.","volume":"198","author":"Stewart AK","year":"2001","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_65_2","unstructured":"Goldschmidt H Bouko Y Bourhis JH et al.CD 34+selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: a randomised study from the EBMT.Blood96: 558a (Abstract) 2000."},{"key":"e_1_2_12_66_2","unstructured":"Fermand JP Marolleau JP Alberti C et al.Single versus tandem high dose therapy supported with autologous stem cell transplantation using unselected or CD 34 enriched ABSC: preliminary results of a two by two designed randomized trial in young patients with multiple myeloma.Blood98: 815a (Abstract) 2001."},{"key":"e_1_2_12_67_2","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood.V91.12.4489","article-title":"Collection, tumor contamination and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.","volume":"91","author":"Tricot G","year":"1998","journal-title":"Blood"},{"key":"e_1_2_12_68_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2001.03189.x"},{"key":"e_1_2_12_69_2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood.V84.3.950.950","article-title":"High\u2010dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.","volume":"84","author":"Vesole D","year":"1994","journal-title":"Blood"},{"key":"e_1_2_12_70_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V88.3.838.838","article-title":"Autotransplant in multiple myeloma: what have we learned?","volume":"88","author":"Vesole D","year":"1996","journal-title":"Blood"},{"key":"e_1_2_12_71_2","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities.","volume":"95","author":"Desikan R","year":"2000","journal-title":"Blood"},{"key":"e_1_2_12_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702826"},{"key":"e_1_2_12_73_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00795.x"},{"key":"e_1_2_12_74_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","article-title":"Age is not a prognostic variable with autotransplants for multiple myeloma.","volume":"93","author":"Siegel DS","year":"1999","journal-title":"Blood"},{"key":"e_1_2_12_75_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02976.x"},{"key":"e_1_2_12_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702188"},{"key":"e_1_2_12_77_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200003"},{"key":"e_1_2_12_78_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03033.x"},{"key":"e_1_2_12_79_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:1:39"},{"key":"e_1_2_12_80_2","first-page":"145","article-title":"Proposed guidelines for protocol studies. II plasma cell myeloma.","volume":"4","author":"Chronic Leukemia\u2010Myeloma Task Force National Cancer Institute.","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_12_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C"},{"key":"e_1_2_12_82_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_12_83_2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1200\/JCO.1986.4.6.888","article-title":"Consolidation and maintenance therapy in multiple myeloma. Randomized comparison of a new approach to therapy after initial response to treatment.","volume":"5","author":"Cohen JH","year":"1986","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.17"},{"key":"e_1_2_12_85_2","doi-asserted-by":"publisher","DOI":"10.1159\/000204379"},{"key":"e_1_2_12_86_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.890"},{"key":"e_1_2_12_87_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3163"},{"key":"e_1_2_12_88_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701559"},{"key":"e_1_2_12_89_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2173"},{"key":"e_1_2_12_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701805"},{"key":"e_1_2_12_91_2","first-page":"7","article-title":"Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy.","volume":"16","author":"Tricot G","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_12_92_2","unstructured":"Sirohi B Powles R Singhal S et al.Second high\u2010dose melphalan autograft for myeloma patients relapsing after one autograft: results equivalent to tandem transplantation.Bone Marrow Transplant29(Suppl. 2): S12 2002."},{"key":"e_1_2_12_93_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006143222402"},{"key":"e_1_2_12_94_2","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non Hodgkin's lymphoma: dose finding and identifications of predictors of response.","volume":"86","author":"Cazzola M","year":"1995","journal-title":"Blood"},{"key":"e_1_2_12_95_2","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinant human erythropoietin in transfusion dependent anemic patients with multiple myeloma and non Hodgkin's lymphoma. A randomized multicentre study.","volume":"87","author":"Osterborg A","year":"1996","journal-title":"Blood"},{"key":"e_1_2_12_96_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1218"},{"key":"e_1_2_12_97_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3412"},{"key":"e_1_2_12_98_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02715.x"},{"key":"e_1_2_12_99_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.131"},{"key":"e_1_2_12_100_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1397"},{"key":"e_1_2_12_101_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00695.x"},{"key":"e_1_2_12_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93075-X"},{"key":"e_1_2_12_103_2","first-page":"723","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma.","volume":"104","author":"McCloskey EV","year":"1999","journal-title":"Br J Haematol"},{"key":"e_1_2_12_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_2_12_105_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"e_1_2_12_106_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.558"},{"key":"e_1_2_12_107_2","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III double blind, comparative trial.","volume":"7","author":"Rosen LS","year":"2001","journal-title":"Cancer J"},{"key":"e_1_2_12_108_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.5191061.x"},{"key":"e_1_2_12_109_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_12_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.273"},{"key":"e_1_2_12_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.tb02158.x"},{"key":"e_1_2_12_112_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.1.80"},{"key":"e_1_2_12_113_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-12-931"},{"key":"e_1_2_12_114_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04314.x"},{"key":"e_1_2_12_115_2","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1182\/blood.V88.5.1780.1780","article-title":"Peripheral blood monoclonal plasma cells as a predictor of survival of patients with multiple myeloma.","volume":"88","author":"Witzig TE","year":"1996","journal-title":"Blood"},{"key":"e_1_2_12_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(05)80205-9"},{"key":"e_1_2_12_117_2","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","article-title":"Plasmablastic morphology: An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group Myeloma Trial E9486 report by the ECOG Myeloma Laboratory Group.","volume":"91","author":"Greipp PR","year":"1998","journal-title":"Blood"},{"key":"e_1_2_12_118_2","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","article-title":"Plasma cell labelling index and \u03b22\u2010microglobulin predict survival independent of thymidine\/kinase and C\u2010reactive protein in multiple myeloma.","volume":"81","author":"Greipp PR","year":"1993","journal-title":"Blood"},{"key":"e_1_2_12_119_2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V85.2.448.448","article-title":"A new staging system for multiple myeloma based on the number of S\u2010phase plasma cells.","volume":"85","author":"San Miguel JF","year":"1995","journal-title":"Blood"},{"key":"e_1_2_12_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(94)00284-I"},{"key":"e_1_2_12_121_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood.V55.3.403.403","article-title":"Cellular DNA content as a marker of human multiple myeloma.","volume":"55","author":"Latreille J","year":"1980","journal-title":"Blood"},{"key":"e_1_2_12_122_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2264(199706)19:2<124::AID-GCC8>3.0.CO;2-0"},{"key":"e_1_2_12_123_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V66.2.338.338","article-title":"Prognostic implication of tumor cell DNA and RNA content in multiple myeloma.","volume":"66","author":"Barlogie B","year":"1985","journal-title":"Blood"},{"key":"e_1_2_12_124_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830300402"},{"key":"e_1_2_12_125_2","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.","volume":"86","author":"Tricot G","year":"1995","journal-title":"Blood"},{"key":"e_1_2_12_126_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00657.x"},{"key":"e_1_2_12_127_2","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase in situ hybridization.","volume":"95","author":"Zojer N","year":"2000","journal-title":"Blood"},{"key":"e_1_2_12_128_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.6.1566"},{"key":"e_1_2_12_129_2","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.V91.9.3366","article-title":"Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes.","volume":"91","author":"Perez\u2010Simon JA","year":"1998","journal-title":"Blood"},{"key":"e_1_2_12_130_2","unstructured":"Jacobson J Barlogie B Shaughnessy J et al.The telling role of cytogenetic abnormalities in predicting clinical outcome of 1000 patients with multiple myeloma after tandem transplants.Blood98: 734a (Abstract) 2001."},{"key":"e_1_2_12_131_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2229"},{"key":"e_1_2_12_132_2","first-page":"185","article-title":"(for the Intergroupe Fancophone du My\u00e8lome). Recurrent 14q32 translocations determine the prognosis of multiple myeloma especially in patients receiving intensive chemotherapy.","volume":"3","author":"Moreau P","year":"2002","journal-title":"Blood"},{"key":"e_1_2_12_133_2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of p53 gene deletion in patients with multiple myeloma predicts for show survival after conventional\u2010dose chemotherapy.","volume":"92","author":"Drach J","year":"1998","journal-title":"Blood"},{"key":"e_1_2_12_134_2","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","article-title":"Activating mutations of N\u2010 and K\u2010ras in multiple myeloma show different clinical association: analysis of the Eastern Cooperative Oncology Group Phase III trial.","volume":"88","author":"Liu P","year":"1996","journal-title":"Blood"},{"key":"e_1_2_12_135_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3793193.x"},{"key":"e_1_2_12_136_2","first-page":"169","volume-title":"Myeloma","author":"Harousseau JL","year":"2002"},{"key":"e_1_2_12_137_2","doi-asserted-by":"publisher","DOI":"10.1038\/332083a0"},{"key":"e_1_2_12_138_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114392"},{"key":"e_1_2_12_139_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V80.3.733.733","article-title":"C\u2010reactive protein and \u03b22 microglobulin produce a sample and powerful myeloma staging system.","volume":"80","author":"Bataille R","year":"1992","journal-title":"Blood"},{"key":"e_1_2_12_140_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1470.x"},{"key":"e_1_2_12_141_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.4721018.x"},{"key":"e_1_2_12_142_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma.","volume":"93","author":"Barlogie B","year":"1999","journal-title":"Blood"},{"key":"e_1_2_12_143_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03231.x"}],"container-title":["Reviews in Clinical and Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-0734.2002.00077.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1468-0734.2002.00077.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T17:20:52Z","timestamp":1697563252000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1468-0734.2002.00077.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":142,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["10.1046\/j.1468-0734.2002.00077.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1468-0734.2002.00077.x","archive":["Portico"],"relation":{},"ISSN":["1127-0020","1468-0734"],"issn-type":[{"value":"1127-0020","type":"print"},{"value":"1468-0734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}